Portfolio yield
Data as at : 30/11/2025
| % |
|---|
| 0.9 |
Please note that the above fields are displayed for companies that have reported this data to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/08/2025
| Investment | % of total assets |
|---|---|
| Boston Scientific Corp | 10.1 |
| Eli Lilly and Co | 9.6 |
| AstraZeneca PLC | 8.3 |
| Stryker Corp | 5.8 |
| Edwards Lifesciences Corp | 5.5 |
| Intuitive Surgical Inc | 5.5 |
| argenx SE ADR | 4.1 |
| Alnylam Pharmaceuticals Inc | 4.0 |
| Caris Life Sciences Inc | 3.8 |
| Other Assets And Liabilities | -4.2 |
Geographic breakdown
Data as at : 30/11/2025
| Country | % of total assets |
|---|---|
| USA | 72.5 |
| UK | 8.4 |
| China | 6.6 |
| Netherlands | 4.8 |
| Japan | 2.8 |
| Hong Kong | 1.6 |
| Belgium | 1.3 |
| Denmark | 0.7 |
| India | 0.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 30/11/2025
| Industry | % of total assets |
|---|---|
| Healthcare | 92.6 |
| Preferred | 3.4 |
| Cash Equivalents | 2.4 |
Asset breakdown
Data as at : 30/11/2025
| Asset | % of total assets |
|---|---|
| Stock | 96.0 |
| Other | 1.6 |
| Cash/Cash equivalents | 2.4 |
Detailed asset breakdown
Data as at : 30/11/2025
| Asset | % of total assets |
|---|---|
| North America - stock | 74.5 |
| UK - Large core/growth stock | 8.4 |
| Asia (excl Japan) - stock | 4.0 |
| Preferred stock | 3.4 |
| Japan - stock | 2.8 |
| Cash | 2.4 |
| Other | 1.6 |
| Europe - Large-cap stock | 1.3 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.